Portable molecular testing offering lab-grade performance in under 30 minutes.
1 This product is under development and performance claims are based on clinical trial data that have not been reviewed by the FDA, see footer for important information.

Traditional diagnostics force a trade-off between accuracy, speed, and cost. Scout's innovative technology eliminates that compromise.
Centers for Disease Control and Prevention. (2024, April 25). SARS-CoV-2 viral shedding and rapid antigen test performance — Respiratory Virus Transmission Network, November 2022–May 2023. Morbidity and Mortality Weekly Report, 73(16), 365–371.
Fast but miss early infections. High false-negative rates lead to undertreated patients.
Molecular accuracy at a lower cost than any other CLIA-waived system
Gold standard performance, but slow turnaround times delay treatments and increases patient loss to follow-up
Scout has been awarded funding from the NIH, CARB-X, and Flu Lab, as well as support from institutions such as Johns Hopkins University and Emory University





"Scout's innovative testing platform allowed Medcor to support our Hollywood productions in remote environments, bypassing lab limitations and enabling beloved shows to continue safely during the pandemic."
Scout is ultra-portable and shelf stable, and can be deployed wherever care is needed (no installation or training required).

Implement low-cost NAAT testing at your practice. Test patients and receive results during their visit, enabling decisive treatment and complete care. Billing may be available using applicable CPT codes, depending on payer policies.